Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels - Full Text View

Purpose

The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with atorvastatin 20 mg in patients with low HDL

Condition	Intervention	Phase
Dyslipidemia	Drug: JTT-705 600 mg and atorvastatin 20 mg Drug: Placebo and atorvastatin 20 mg	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels

Resource links provided by NLM:

Drug Information available for: Atorvastatin Atorvastatin calcium Atorvastatin calcium trihydrate

U.S. FDA Resources

Further study details as provided by Akros Pharma Inc.:

Primary Outcome Measures:

% change from baseline in HDL-C; inhibition of CETP activity [ Time Frame: 4-weeks ]

Secondary Outcome Measures:

% change from baseline in LDL-C and TC/HDL-C [ Time Frame: 4-weeks ]
Plasma concentration of JTT-705 [ Time Frame: 4-weeks ]


Enrollment:	105
Study Start Date:	January 2004
Study Completion Date:	March 2006
Primary Completion Date:	November 2004 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 JTT-705 600 mg and atorvastatin 20 mg	Drug: JTT-705 600 mg and atorvastatin 20 mg JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments
Placebo Comparator: 2 Placebo and atorvastatin 20 mg	Drug: Placebo and atorvastatin 20 mg Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients having lipid values as indicated below:
- HDL-C ≤ 1.0 mmol/L (40 mg/dL)
- TG ≤4.5 mmol/L (400 mg/dL)
Patients with CHD or CHD risk equivalent
Male and females between 18 and 70 years of age (female patients must be post-menopausal, surgically sterile or using an acceptable form of contraception)

Exclusion Criteria:

Body Mass Index of ≥ 35 kg/m2
Females that are pregnant or breast-feeding, and females of child bearing potential who are not using an effective method of contraception
Concomitant use of medications identified in the protocol

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00689442

Locations


Netherlands

Amsterdam, Netherlands

Sponsors and Collaborators

Akros Pharma Inc.

More Information


Responsible Party:	Shoji Hoshino, DVM, Vice President, Clinical Development, Akros Pharma Inc.
ClinicalTrials.gov Identifier:	NCT00689442 History of Changes
Other Study ID Numbers:	AT705-X-03-002
Study First Received:	May 29, 2008
Last Updated:	June 2, 2008

Additional relevant MeSH terms:


Dalcetrapib Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Atorvastatin Calcium Anticholesteremic Agents	Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 26, 2017